Weiss Ratings Reaffirms Sell (E+) Rating for Tharimmune (NASDAQ:THAR)

Tharimmune (NASDAQ:THAR)‘s stock had its “sell (e+)” rating reaffirmed by equities research analysts at Weiss Ratings in a research report issued to clients and investors on Wednesday,Weiss Ratings reports.

Separately, Wall Street Zen raised Tharimmune to a “hold” rating in a research note on Friday, October 3rd. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $17.00.

Tharimmune Stock Performance

THAR opened at $3.18 on Wednesday. The stock has a market cap of $18.76 million, a price-to-earnings ratio of -0.52 and a beta of 1.41. The stock’s 50 day moving average price is $3.08 and its 200-day moving average price is $2.01. Tharimmune has a one year low of $0.95 and a one year high of $9.08.

Tharimmune (NASDAQ:THAR) last released its earnings results on Thursday, August 14th. The company reported ($0.64) EPS for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.06).

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Tharimmune stock. XTX Topco Ltd bought a new position in shares of Tharimmune, Inc. (NASDAQ:THAR) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 12,911 shares of the company’s stock, valued at approximately $25,000. XTX Topco Ltd owned 0.31% of Tharimmune as of its most recent SEC filing. Institutional investors own 1.16% of the company’s stock.

About Tharimmune

Tharimmune, Inc, a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1).